| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | MYCOBACTERIA THERAPEUTICS CORPORATION | 114 OLD LOGGING RD | GOLDEN | CO | 80403-9591 | JEFFERSON | USA | R41AT011390 | Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD | 000 | 2 | NIH | 12/22/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $319,076 ) |
| | 2022 | 2022 | MYCOBACTERIA THERAPEUTICS CORPORATION | 114 OLD LOGGING RD | GOLDEN | CO | 80403-9591 | JEFFERSON | USA | R41AT011390 | Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD | 000 | 2 | NIH | 12/14/2021 | $319,076 |
|
| Issue Date FY: 2021 ( Subtotal = $42,157 ) |
| | 2021 | 2021 | MYCOBACTERIA THERAPEUTICS CORPORATION | 114 OLD LOGGING RD | GOLDEN | CO | 80403-9591 | JEFFERSON | USA | R41AT011390 | Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD | 002 | 1 | NIH | 8/11/2021 | $42,157 |
| | 2021 | 2020 | MYCOBACTERIA THERAPEUTICS CORPORATION | 114 OLD LOGGING RD | GOLDEN | CO | 80403-9591 | JEFFERSON | USA | R41AT011390 | Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD | 000 | 1 | NIH | 5/27/2021 | $0 |
| | 2021 | 2020 | MYCOBACTERIA THERAPEUTICS CORPORATION | 114 OLD LOGGING RD | GOLDEN | CO | 80403-9591 | JEFFERSON | USA | R41AT011390 | Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD | 001 | 1 | NIH | 8/11/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $282,843 ) |
| | 2020 | 2020 | MYCOBACTERIA THERAPEUTICS CORPORATION | 3132 BELL DRIVE | BOULDER | CO | 80301-2278 | BOULDER | USA | R41AT011390 | Lead compound discovery from proprietary mycobacterial strains for treatment of PTSD | 000 | 1 | NIH | 9/18/2020 | $282,843 |
|
|
